Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Freedom Fighter who wrote (85973)	11/28/2000 6:00:55 PM
From: Knighty Tin	Respond to of 132070

Wayne, the company is terrific and has a lock on the low end of the genomics game. However, the stock got downright silly ($276 a share! Man, your club's $60 looks downright judicial compared to that). I still don't consider it cheap, but, like Ballard Power, I have a lot of faith in their future. I'm not buying either stock, too risky, but for long calls in the 90/10 portfolio, they are starting to look tempting.

To: Freedom Fighter who wrote (85973)	11/28/2000 9:49:41 PM
From: Spekulatius	Read Replies (1) \| Respond to of 132070

While I also like CRA is like INCY much more so as a LT investment. INCY has been in the gen-database business much longer and 19 of the 20 largest drug companies subscribe their database. incyte.com This gives INCY not only the current subscription fees, but even more importantly a small royalty on every drug that is being developed with their database. A while ago, the INCY CEO stated in a CC, that half of Astra-Zeneca's current pipeline is developed with INCY data. If this is true for all the 18 other drug companies working with INCY databases, this could add up to hundreds of millions $ in cash royalties per year. I also consider it important,that VRTX, a fully integrated biotech has chosen INCY instead of CRA. While I consider CRA a viable competitor, I prefer INCY as an investment, because of a 5 year headstart in business development, potentially very valuable genomics IP, and more "downstream genomics" activities. That said, both have an extremely strong balance sheet - CRA has about 1B$ and INCY a cool 700M$ in cash. OK,everything IMO. (I own INCY of course).